IPO Year: 2021
Exchange: NASDAQ
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
NT 10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
10-Q - Ocean Biomedical, Inc. (0001869974) (Filer)
10-Q/A - Ocean Biomedical, Inc. (0001869974) (Filer)
10-Q/A - Ocean Biomedical, Inc. (0001869974) (Filer)
NT 10-K - Ocean Biomedical, Inc. (0001869974) (Filer)
8-K - Ocean Biomedical, Inc. (0001869974) (Filer)
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria parasites, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infect
PROVIDENCE, Rhode Island, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the yea
Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 - 8. The late breaker Phase 1b data presen
PROVIDENCE, Rhode Island, May 30, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with res
Providence, RI, May 16, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been granted a new patent for his malaria therapeutic antibody discoveries, targeted to both prevent malaria infection and treat severe malaria. Kurtis' novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This expands patent protection for Dr. Kurtis' novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs. This patent is adding to Ocean Biomedical's global patent po
PROVIDENCE, Rhode Island, April 24, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-K as a result of previously disclosed developments wi
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker oral presentation highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27 - 31. The late breaker Phase 1 data presente
Providence, RI, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company which endeavors to accelerate the development of compelling discoveries from top research scientists, today congratulates its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing T cell-based immunotherapies, for the acceptance of their abstract highlighting the first-ever human data from its novel checkpoint modifier immunotherapy for HBV functional cure, for late breaker oral presentation at the upcoming 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27-3
Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The groundbreaking discoveries by
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its quarterly report on Form 10-Q for the period ended September 30, 2023 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q. On November 9, 2023, Ocean Biomedical received
3 - Ocean Biomedical Holdings, Inc. (0001836612) (Issuer)
Gainers Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. The market value of their outstanding shares is at $7.1 million. Akanda (NASDAQ:AKAN) stock rose 7.74% to $2.92. The company's market cap stands at $5.5 million. LifeMD (NASDAQ:LFMD) stock rose 5.81% to $8.0. The market value of their outstanding shares is at $327.0 million. Purple Biotech (NASDAQ:PPBT) shares rose 5.79% to $0.58. The company's market cap stands at $15.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 5.29% to $0.44. The market value of their outstanding shares is at $2.0 million. Compass Therapeutics (NASDAQ:CMPX) shares increased by 4.95% to $1.27. The
As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023.
Gainers Arcutis Biotherapeutics (NASDAQ:ARQT) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. BioAtla (NASDAQ:BCAB) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. OptimizeRx (NASDAQ:OPRX) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 m
Gainers Emergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. Nuwellis (NASDAQ:NUWE) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. Syra Health (NASDAQ:SYRA) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. Titan Pha
Shares of Koninklijke Philips N.V. (NYSE:PHG) rose sharply in today's pre-market trading after reporting first-quarter results. The company also resolved the respironics personal injury and medical monitoring litigation in the US for $1.1 billion. Koninklijke Philips shares jumped 37.1% to $28.87 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Inno Holdings Inc. (NASDAQ:INHD) gained 33.8% to $0.8410 in pre-market trading. Ryde Group Ltd. (NYSE:RYDE) gained 25.9% to $4.18 in pre-market trading after dipping 8% on Friday. Akanda Corp. (NASDAQ:AKAN) climbed 21.4% to $0.1250 in pre-market trading after gaining over 12% on Friday. Ocea
Gainers NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Recovery (NASDAQ:LIFW) shares rose 29.74% to $1.23. The company's market cap stands at $19.5 million. Assure Hldgs (NASDAQ:IONM) stock increased by 24.31% to $0.55. The market value of their outstanding shares is at $4.9 million. ProKidney (NASDAQ:PROK) stock increased by 22.79% to $2.5. The company's market cap stands at $154.3 million. iSpecimen (NASDAQ:ISPC) shares increased by 19.32% to $0.34. The company's market cap stands at $3.1 million. GlucoTrack (NASDAQ:GCTK) stock moved upwards b
Shares of HighPeak Energy, Inc. (NASDAQ:HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. HighPeak Energy posted GAAP earnings of 66 cents per share, versus market estimates of 65 cents per share. The company’s quarterly sales came in at $301.153 million versus expectations of $339.525 million. HighPeak Energy shares declined 15.3% to $13.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) shares jumped 404% to $11.65 after the company announced the launch of Lytus Cloud. CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) gained
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 28.74% to $0.99. The company's market cap stands at $4.5 million. Creative Medical Tech (NASDAQ:CELZ) stock increased by 28.18% to $6.1. The market value of their outstanding shares is at $8.4 million. HeartBeam (NASDAQ:BEAT) stock rose 26.53% to $2.05. The company's market cap stands at $53.9 million. Ocean Biomedical (NASDAQ:OCEA) shares increased by 24.4% to $5.03. The market value of their outstanding shares is at $171.3 million. Quantum-Si (NASDAQ:QSI)